Program
Anti-STEAP2/Exatecan Antibody-drug Conjugate AZD0516
Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.
Furthest: phase 2, since Sep 12, 20251 company-led study, 1 open or runningNext primary completion: Jan 18, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Sep 12, 2025 | Sep 12, 2025 | Jan 18, 2029phase 2 · NCT07181161 |
- Named in AstraZeneca’s own pipeline as
AZD0516
, phase 1, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07181161 · 283 planned · United States, Brazil, China and more
Ahead
- Jan 18, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07181161
TargetBeta
“An antibody-drug conjugate (ADC) composed of a Fc-engineered monoclonal antibody targeting the tumor-associated antigen (TAA) six-transmembrane epithelial antigen of the prostate-2 (STEAP2; STEAP-2; STAMP1), linked via interchain cysteines to a maleimide-reactive, beta-glucuronidase-cleavable lin…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a Fc-engineered monoclonal antibody targeting the tumor-associated antigen (TAA) six-transmembrane epithelial antigen of the prostate-2 (STEAP2; STEAP-2; STAMP1), ”NCIt, by rule
Other programs on STEAP2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| STEAP2-targeting Radioconjugate AZD2287rule | AstraZeneca | phase 2 | 2 |
| Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754 | AstraZeneca | phase 2 | 1 |
| Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621 | AstraZeneca | phase 2 | 1 |
| AZD8359rule | AstraZeneca | phase 2 | 1 |
| Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284 | AstraZeneca | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07181161Prostatic Neoplasms · United States, Brazil, China and more | 2 | Recruiting | Jan 18, 2029 | 283 |
How it is read
Names in the registry
- “AZD0516”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.